Introduction. Human papillomaviruses (Human Papillomavirus-HPV) are DNA viruses, belonging to the family Papillomaviridae, genus Papillomavirus. It is estimated that at least 80%-100% of people between the ages of 18-25 come into contact with this virus during sexual contact, while only about 30% of people develop symptoms of infection. Chronic HPV infection increases the risk of cervical cancer by 65 times, and in the case of oncogenic “high-risk” types by 130 times (HPV 16, HPV 18, HPV 31, HPV 35), namely cancer of the cervix, vulva and vagina in women, genital organs in men, as well as throat and anus cancer in both sexes. CIN within the framework of HPV infection and pathogenesis can be viewed as a productive infection (replicative) that is most often transient and spontaneously regresses (viral phase) and transformational with the development of dysplasia in a smaller number of HPV-infection-related lesions (neoplastic phase). As a preventive measure, there are vaccines against HPV (Gardasil, Gardasil 9 and Cervarix), which are not mandatory according to the vaccination calendar and contribute to preventing the development of HPV infection, and are particularly effective in the fight against HPV types 16 and 18, which in most cases cause cervical cancer. The aim of this work is to compare the obtained data on the optional Gardasil 9 vaccination carried out on the territory of Pomoravlje and Pcinja districts in Serbia in the year 2022. Methodology of the research work. A descriptive study was applied in this research paper. A special database was created for data entry in the time interval in year 2022. The data were calculated in the SPSS Statistics 20 software package. The data were presented graphically. Results and discussion. Based on statistically processed data, it can be seen that in the south of Serbia, out of the total number of distributed vaccines, which was 253 vaccines for the Pcinja district, 86 vaccines (33.99%) were administered. Comparing the data with the Pomoravlje district, there is a significant difference in the number of distributed (769) and the number of applied vaccines (408), which indicates that 53.06% of the distributed doses were applied for the period from June 2022 by the end of the same year. Statistical processing of the obtained data showed that the Gardasil 9 vaccination with the first and second doses of the vaccine in persons older than 9 years and persons older than 15 years was best carried out in 2022 in the Pomoravlje District in the cities of Jagodina (59.41%) and Svilajnac (54.02%), and the smallest in the cities of Rekovac (35, 71%) and Cuprija (40.35%). While the least was implemented in the territory of the Pcinja District in 2022 were in the cities: Bosilegrad, Presevo and Trgoviste based on distributed doses and remaining unused vaccines (stock). The highest response for optional free vaccination was in the cities of Surdulica (66.675%), Bujanovac (39.58%) and Vranje (36.36%) in Pcinja District. Conclusion. By comparing the statistical data, it can be concluded that the success rate of vaccination is significantly higher in central Serbia, in the territory of the Pomoravlje District (53.06%), than in the south of Serbia, in the territory of the Pcinja District (33.99%). Through educational lectures on vaccination against HPVirus, children, adults and the entire population acquire positive attitudes about prevention as one of the most effective methods in suppressing and spreading the said disease.

1. M. Muller et al., “Chimeric papillomavirus-like particles,” Virology , vol. 234, no. 1, pp. 93 – 111, Jul. 1997.
   DOI: 10.1006/viro.1997.8591
   PMid: 9234950
2. E. M. Smith et al., “Human papillomavirus and risk of laryngeal cancer,” Ann. Otol. Rhinol. Laryngol., vol. 109, no. 11, pp. 1069 – 1076, Nov. 2000.
   DOI: 10.1177/000348940010901114
   PMid: 11090000
3. J. S. Smith et al., “Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update,” Int. J. Cancer, vol. 121, no. 3, pp. 621 – 632, Aug. 2007.
   DOI: 10.1002/ijc.22527
   PMid: 17405118
4. D. M. Da Silva et al., “Physical interaction of human papillomavirus virus-like particles with immune cells,” Int. Immunol., vol. 13, no. 5, pp. 633 – 641, May 2001.
   DOI: 10.1093/intimm/13.5.633
   PMid: 11312251
5. F. X. Bosch et al., “Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia,” Vaccine, vol. 26, suppl. 10, pp. K1 – K16, Aug. 2008.
   DOI: 10.1016/j.vaccine.2008.05.064
   PMid: 18847553
6. D. Dias et al., “Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18,” Clin. Diagn. Lab. Immunol., vol. 12, no. 8, pp. 959 – 969, Aug. 2005.
   DOI: 10.1128/CDLI.12.8.959-969.2005
   PMid: 16085914
   PMCid: PMC1182182
7. L. K. Borysiewicz et al., “A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer,” Lancet, vol. 347, no. 9014, pp. 1523 – 1527, Jun. 1996.
   DOI: 10.1016/s0140-6736(96)90674-1
   PMid: 8684105
8. D. M. Harper et al., “Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial,” Lancet, vol. 364, no. 9447, pp. 1757 – 1765, Nov. 2004.
   DOI: 10.1016/S0140-6736(04)17398-4
   PMid: 15541448
9. G. M. Clifford, J. S. Smith, M. Plummer, N. Munoz, S. Franceschi, “Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis,” Br. J. Cancer, vol. 88, no. 1, pp. 63 – 73, Jan. 2003.
   DOI: 10.1038/sj.bjc.6600688
   PMid: 12556961
   PMCid: PMC2376782
10. A. T. Lorincz et al., “Human papillomavirus infection of the cervix: relative risk associations of 15 common anogenital types,” Obstet. GynecoI., vol. 79, no. 3, pp. 328 – 337, Mar. 1992.
    DOI: 10.1097/00006250-199203000-00002
    PMid: 1310805
11. J. R. Daling et al., “A population-based study of squamous cell vaginal cancer: HPV and cofactors,” Gynecol. Oncol., vol. 84, no. 2, pp. 263 – 270, Feb. 2002.
    DOI: 10.1006/gyno.2001.6502
    PMid: 11812085
12. T. C. Wright, T. V. Ellerbrock, M. A. Chiasson, N. Van Devanter, X. W. Sun, “Cervical intraepithelial neoplasia in women infected with human immunodeficiency virus: Prevalence, risk factors, and validity of Papanicolaou smears,” Obstet. Gynecol., vol. 84, no. 4, pp. 591 – 597, Oct. 1994.
    Retrieved from: https://pubmed.ncbi.nlm.nih.gov/8090399/
    Retrieved on: May 20, 2023
13. K. B. Michels, H. Z. Hausen, “HPV vaccine for all,” Lancet, vol. 374, no. 9686, pp. 268 – 270, Jul. 2009.
    DOI: 10.1016/S0140-6736(09)61247-2
    PMid: 19586657
14. L. L. Villa et al., “Immunologic responses following administration of a vaccine targeting human papillomavirus Types 6, 11, 16, and 18,” Vaccine , vol. 24, no. 27-28, pp. 5571 – 5583, Jul. 2006.
    DOI: 10.1016/j.vaccine.2006.04.068
    PMid: 16753240
15. K. Schafer et al., “Immune response to human papillomavirus 16 L1E7 chimeric virus-like particles: induction of cytotoxic T cells and specific tumor protection,” Int. J. Cancer, vol. 81, no. 6, pp. 881 – 888, Nov. 1999.
    Retrieved from: https://onlinelibrary.wiley.com/doi/10.1002/(SICI)1097-0215(19990611)81:6%3C881::AID-IJC8%3E3.0.CO;2-T
    Retrieved on: May 20, 2023
16. P. Mayaud, D. Mabey, “Approaches to the control of sexually transmitted infections in developing countries: old problems and modern challenges,” Sex. Transm. Infect., vol. 80, no. 3, pp. 174 – 182, Jun. 2004.
    DOI: 10.1136/sti.2002.004101
    PMid: 15169997
    PMCid: PMC1744836
17. R. E. Rupp, L. R. Stanberry, S. L. Rosenthal, “Vaccines for sexually transmitted infections,” Pediatr. Ann. , vol. 34, no. 10, pp. 818 – 824, Oct. 2005.
    DOI: 10.3928/0090-4481-20051001-14
    PMid: 16285635
18. S. H. Vermund et al., “High risk of human papillomavirus infection and cervical squamous intraepithelial lesions among women with symptomatic human immunodeficiency virus infection,” Am. J. Obstet. Gynecol., vol. 165, no. 2, pp. 392 – 400, Aug. 1991.
    DOI: 10.1016/0002-9378(91)90101-v
    PMid: 1651648
19. J. Berumen et al., “Asian-American variants of human papillomavirus 16 and risk for cervical cancer: a case-control study,” J. Natl. Cancer Inst. , vol. 93, no. 17, pp. 1325 – 1330, Sep. 2001.
    DOI: 10.1093/jnci/93.17.1325
    PMid: 11535707
20. F. X. Bosch et al., “Prevalence of human papillomavirus in cervical cancer: a worldwide perspective. International biological study on cervical cancer (IBSCC) Study Group,” J. Natl. Cancer Inst., vol. 87, no. 11, pp. 796 – 802, Jun. 1995.
    DOI: 10.1093/jnci/87.11.796
    PMid: 7791229
21. A. N. Fiander et al., “Prime-boost vaccination strategy in women with high-grade, noncervical anogenital intraepithelial neoplasia: clinical results from a multicenter phase II trial,” Int. J. Gynecol. Cancer, vol. 16, no. 3, pp. 1075 – 1081, Jun. 2006.
    DOI: 10.1111/j.1525-1438.2006.00598.x
    PMid: 16803488
22. Y. Lu et al., “Immunological protection against HPV16 E7-expressing human esophageal cancer cell challenge by a novel HPV16-E6/E7 fusion protein based vaccine in a Hu-PBL-SCID mouse model,” Biol. Pharm. Bull., vol. 30, no. 1, pp. 150 – 156, Jan. 2007.
    DOI: 10.1248/bpb.30.150